Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis

Table 3 Patterns of recurrence and postoperative treatments in the patients of the two groups, n (%)

	NLR ≤ 2.9	NLR > 2.9	P value
Recurrence	n = 51	n = 30	1.000
Negative	3 (5.9)	1 (3.3)
Positive	39 (76.5)	23 (76.7)
Unknown	9 (17.6)	6 (20)
Recurrence pattern	n = 39	n = 23	0.832
Intrahepatic only	26 (66.7)	15 (65.2)
Extrahepatic only	2 (5.1)	2 (8.7)
Both	11 (28.2)	6 (26.1)
Treatments	n = 51	n = 30
TACE	23	15
Hepatectomy	2	0
PMCT	4	0
Systemic chemotherapy	3	2
RFA	5	0
PEI	2	0
CIK	0	2
TAI	1	1
Sorafenib	0	1
Radiotherapy	1	0
Sealed source radiotherapy	1	2
Traditional Chinese medicine	4	0
Supportive care only	21	12

Some patients accepted more than one type of treatment. NLR: Neutrophil-to-lymphocyte ratio; TACE: Transarterial chemoembolization; PMCT: Percutaneous microwave tumor coagulation therapy.